Neural Analytics wins US DoD contract to develop device to assess TBI

26 October 2017 (Last Updated October 27th, 2017 11:59)

Neural Analytics has secured a contract from the US Department of Defense (DoD) to develop a portable, point of injury device to assess combat-related traumatic brain injury (TBI).

Neural Analytics wins US DoD contract to develop device to assess TBI
Point of injury device for assessing combat-related traumatic brain injury. Credit: Business Wire.

Neural Analytics has secured a contract from the US Department of Defense (DoD) to develop a portable, point of injury device to assess combat-related traumatic brain injury (TBI).

The $10m deal stipulates that the company should develop a new lucid system within the next 18 months.

The new device must be able to measure and monitor various physiological parameters relevant to moderate-severe TBI, as well as be capable of operating in prolonged field case scenarios.

Battelle has been selected to provide technical and advanced engineering expertise to enable ruggedisation and miniaturisation in accordance with military requirements.

Neural Analytics co-founder and chief executive officer Leo Petrossian said: “We are honoured to continue our partnership with the US Army to further advance point of care injury management of brain health.

“We believe our technology will be the first of its kind targeted for a military environment.

“We are honoured to continue our partnership with the US Army to further advance point of care injury management of brain health.”

“This work will also significantly impact civilian versions of the technology, allowing for further advancement of our Lucid System in the pre-hospital or EMS setting.”

The system is expected to be operated as a single, portable unit, while requiring minimal training and maintenance.

Work under the contract will be supported by the US Army Medical Research and Materiel Command.

Neural Analytics intends to continue to supply the system to the DoD upon completing development of the assessment device, as well as commercialise the technology into its civilian brain health platforms.